Malaria vaccine, Lower Level Infection

CHICAGO, MONDAY - malaria vaccine being tested in phase can reduce infection rates and disease in children up to 53-65 percent in two clinical trials conducted in Africa. Efforts to develop a vaccine for the deadly disease has been conducted in various research for more than 70 years old.

"This is the first candidate malaria vaccine showed significant protection based on the results of laboratory tests and field-based clinical studies," said William Collins and John Barnwell of the Center for Disease Control and Prevention (Centers for Disease and Prevention) in his writings on the New England Journal of Medicine, Monday (8/12) in Chicago, U.S.

The vaccine was first developed by GlaxoSmithKline, an international pharmaceutical company, the late 1980s, and has been tested to the volunteers in the United States.

Malaria transmitted by mosquito bites, and each year kills about one million people and infects 250 million people. "Malaria vaccine is difficult to develop because there are several stages of the disease," said the child's allergist and immunologist from the Medical Faculty University of Indonesia-Cipto Mangunkusumo Hospital, Zakiudin Munazir, yesterday in Jakarta.